Press Releases

Oct 22, 2020

Apr 28, 2020

ProBioGen AG appoints Dr. Lutz Hilbrich as new Chief Executive Officer - Dr. Wieland Wolf retires

Mar 24, 2020

Immunogenesis contracts ProBioGen for Development and Large-Scale Manufacturing Services

Feb 25, 2020

ImmunOs Therapeutics selects ProBioGen for Development and Large-Scale Manufacturing Services

Jan 14, 2020

ProBioGen and Lava Therapeutics Sign Cell Line Development and GMP Manufacturing Agreement for Novel Bispecific Molecule

Jan 08, 2020

ProBioGen inks next Commercial GlymaxX® License with Roche

Nov 07, 2019

DirectedLuck, a Transposase for Efficient Gene Delivery and High-Titer Cell Line Development

Oct 01, 2019

ProBioGen and Ceva Santé Animale sign an exclusive license agreement to produce vectorised poultry vaccines using AGE1.CR® production technology

Sep 10, 2019

ProBioGen licenses GlymaxX® Technology to Bayer

May 23, 2019

ProBioGen and Abcuro signed GlymaxX®-Improved Cell Line Development and GMP Production Agreement

Page 5 of 11

Press Releases

Heidelberg Pharma contracts ProBioGen for Cell Line Development and Manufacturing Services

ProBioGen AG appoints Dr. Lutz Hilbrich as new Chief Executive Officer - Dr. Wieland Wolf retires

Immunogenesis contracts ProBioGen for Development and Large-Scale Manufacturing Services

ImmunOs Therapeutics selects ProBioGen for Development and Large-Scale Manufacturing Services

ProBioGen and Lava Therapeutics Sign Cell Line Development and GMP Manufacturing Agreement for Novel Bispecific Molecule

ProBioGen inks next Commercial GlymaxX® License with Roche

DirectedLuck, a Transposase for Efficient Gene Delivery and High-Titer Cell Line Development

ProBioGen and Ceva Santé Animale sign an exclusive license agreement to produce vectorised poultry vaccines using AGE1.CR® production technology

ProBioGen licenses GlymaxX® Technology to Bayer

ProBioGen and Abcuro signed GlymaxX®-Improved Cell Line Development and GMP Production Agreement